NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it is expected to be added to the Russell Microcap® Index as part of the first semi-annual reconstitution of the Russell US Indexes in 2026. The preliminary inclusion lists were published by FTSE Russell on May 22, May 29, and June 5, 2026. The newly reconstituted indexes will take effect after the US market close on Friday, June 26, 2026.
Dave Rosa, Chief Executive Officer of NeuroOne, commented, “We are pleased that NeuroOne is expected to be added to the Russell Microcap® Index. We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community. We expect membership in the index to expand our visibility among institutional investors and broaden our shareholder base as we continue our mission of transforming the treatment of neurological disorders.”
For investors, inclusion in the Russell Microcap Index is significant because it often leads to increased demand for a company's shares from index funds and exchange-traded funds that track the index. This can provide a more stable shareholder base and potentially improve liquidity. The move also signals that NeuroOne has met the market capitalization and other criteria required for index membership, which may enhance its credibility with the broader investment community.
NeuroOne is a medical technology company focused on improving surgical care for patients with neurological disorders. The company markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
FTSE Russell recently announced that the reconstitution of the Russell US Indexes is changing from an annual to a semi-annual schedule beginning in 2026, which provides more frequent opportunities for companies to be added or removed based on changes in market capitalization. This shift may lead to more dynamic index compositions.
Forward-looking statements in the press release reflect NeuroOne's current views about future events and are subject to known and unknown risks, including uncertainties related to the company's capital requirements, regulatory approvals, and market acceptance of its technology. NeuroOne undertakes no obligation to update these statements.
